{"id":"W4236986578","doi":"10.1158/1538-7445.sabcs16-ot2-01-01","title":"Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with <i>PIK3CA-</i>mutant tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Calgary","funders":"","keywords":"Fulvestrant; Metastatic breast cancer; Medicine; Internal medicine; Estrogen receptor; Cancer; Aromatase inhibitor; Breast cancer; Oncology; Estrogen; Placebo; PI3K/AKT/mTOR pathway; Endocrinology; Cancer research; Aromatase; Biology; Pathology; Apoptosis; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009560571,0.001549696,0.001381598,0.0003879211,0.0003331698,0.000918362,0.000885232,0.001117631,0.004992795],"category_scores_gemma":[0.0005997876,0.0004887385,0.001162029,0.0004333672,0.0009889939,0.0008115979,0.0002833431,0.002332603,0.0008558986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001115965,"about_ca_system_score_gemma":0.002023678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002468437,"about_ca_topic_score_gemma":0.006346297,"domain_scores_codex":[0.9997581,0.0000963421,0.00001080143,0.00004178065,0.00002265744,0.00007026712],"domain_scores_gemma":[0.9996295,0.00005093463,0.00007123163,0.00002817928,0.00002135922,0.0001987456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8596918,0.03493451,0.00319198,0.0009414562,0.001314838,0.0001837237,0.0001437024,0.00206607,0.04117142,0.0004433219,0.005831022,0.05008611],"study_design_scores_gemma":[0.7680119,0.2200045,0.00566102,0.00002970036,0.0004027488,0.0001323099,0.0000324361,0.00105167,0.002990173,0.0001414109,0.001518177,0.00002405142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895704,0.001262059,0.0005146266,0.0004872826,0.0001180815,0.003184942,0.002139592,0.0002416169,0.00248141],"genre_scores_gemma":[0.9817851,0.001463135,0.002158393,0.001082985,0.0001768823,0.003802753,0.004609555,0.00004043364,0.004880776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004992795,"threshold_uncertainty_score":0.01670253,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02965572347447072,"score_gpt":0.3682503041920291,"score_spread":0.3385945807175584,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}